Q-omics provides the consensus-scored COL6A4P2 profile across patient tissues and cancer cell-line models. COL6A4P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COL6A4P2 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, COL6A4P2 RNA expression shows 15,993 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where COL6A4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL6A4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL6A4P2 survival associations across molecular data types. COL6A4P2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL6A4P2 RNA expression–survival associations across cancer types. High COL6A4P2 expression shows unfavorable associations in KIRC, COAD, LUSC and THCA, but favorable associations in HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COL6A4P2 RNA expression.
This table summarizes COL6A4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for COL6A4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL6A4P2 shows lower tumor expression in KIRP and KICH and higher tumor expression in LUAD, COAD, BLCA and CHOL. The KIRP box plot shows higher COL6A4P2 RNA expression in normal versus tumor tissue (log2 FC = −0.450, t-test p < 0.001).
This table shows molecular features associated with COL6A4P2 in patient tissues and cancer cell lines. In patient samples, COL6A4P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
